Literature DB >> 17376256

Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients.

H E Gary1, B Smith, J Jenks, J Ruiz, W Sessions, J Vinje, M Sobsey.   

Abstract

While oral polio vaccine (OPV) has been shown to be safe and effective, it has been observed that it can circulate within a susceptible population and revert to a virulent form. Inactivated polio vaccine (IPV) confers protection from paralytic disease, but provides limited protection against infection. It is possible, then, that an IPV-immunized population, when exposed to OPV, could sustain undetected circulation of vaccine-derived poliovirus. This study examines the possibility of polio vaccine virus circulating within the United States (highly IPV-immunized) population that borders Mexico (OPV-immunized). A total of 653 stool and 20 sewage samples collected on the US side of the border were tested for the presence of poliovirus. All samples were found to be negative. These results suggest that the risk of circulating vaccine-derived poliovirus is low in fully immunized IPV-using populations in developed countries that border OPV-using populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376256      PMCID: PMC2870796          DOI: 10.1017/S0950268807008321

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

1.  Isolation of polioviruses from sewage and their characteristics: experience over two decades in Sweden.

Authors:  M Böttiger; E Herrström
Journal:  Scand J Infect Dis       Date:  1992

2.  Present position of immunization against poliomyelitis with live virus vaccines.

Authors:  A B SABIN
Journal:  Br Med J       Date:  1959-03-14

Review 3.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication.

Authors:  Olen M Kew; Roland W Sutter; Esther M de Gourville; Walter R Dowdle; Mark A Pallansch
Journal:  Annu Rev Microbiol       Date:  2005       Impact factor: 15.500

4.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.

Authors:  I M Onorato; J F Modlin; A M McBean; M L Thoms; G A Losonsky; R H Bernier
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

5.  Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic.

Authors:  W M MARINE; T D CHIN; C R GRAVELLE
Journal:  Am J Hyg       Date:  1962-09

Review 6.  Eradication of poliomyelitis in the United States. II. Experience with killed poliovirus vaccine.

Authors:  D Salk
Journal:  Rev Infect Dis       Date:  1980 Mar-Apr

7.  Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-09-30       Impact factor: 17.586

8.  Poliovirus infections in four unvaccinated children--Minnesota, August-October 2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-10-21       Impact factor: 17.586

9.  Isolation and characterization of circulating type 1 vaccine-derived poliovirus from sewage and stream waters in Hispaniola.

Authors:  Jan Vinjé; Nicole Gregoricus; Javier Martin; Howard E Gary; Victor M Caceres; Linda Venczel; Andrew Macadam; James G Dobbins; Cara Burns; Douglas Wait; Gwangpyo Ko; Mauricio Landaverde; Olen Kew; Mark D Sobsey
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

  9 in total
  3 in total

1.  Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.

Authors:  Sebastian Zurbriggen; Kurt Tobler; Carlos Abril; Sabine Diedrich; Mathias Ackermann; Mark A Pallansch; Alfred Metzler
Journal:  Appl Environ Microbiol       Date:  2008-07-18       Impact factor: 4.792

Review 2.  Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Authors:  Radboud J Duintjer Tebbens; Marita Zimmermann; Mark A Pallansch; Kimberly M Thompson
Journal:  Food Environ Virol       Date:  2017-07-07       Impact factor: 2.778

3.  Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru.

Authors:  Janice Seinfeld; María Laura Rosales; Alfredo Sobrevilla; Juan Guillermo López Yescas
Journal:  BMC Health Serv Res       Date:  2022-05-16       Impact factor: 2.908

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.